Publicaciones en colaboración con investigadores/as de Medical University of Lublin (5)

2020

  1. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

    Blood Cancer Journal, Vol. 10, Núm. 9

2015

  1. Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up

    British Journal of Haematology, Vol. 171, Núm. 3, pp. 344-354

  2. Elotuzumab therapy for relapsed or refractory multiple myeloma

    New England Journal of Medicine, Vol. 373, Núm. 7, pp. 621-631

2013

  1. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma

    Journal of Clinical Oncology, Vol. 31, Núm. 2, pp. 247-255

2008

  1. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

    New England Journal of Medicine, Vol. 359, Núm. 9, pp. 906-917